2014年阿片类药物致死人数大爆发及应对策略

2015-12-22 QQduhq译 MedSci原创

2014年死于药物滥用的民众比有数据记录的任何一年都要多,据CDC今年发布的最新数据显示,因阿片类药物使用过量导致的民众死亡占主要原因。2014年,阿片类药物使用过量导致民众死亡的人数(包括死于阿片类止痛药和海洛因的患者人数)达到历史新高,较往年增加了14%。

 
阿片类止痛药(天然和半合成阿片类药物)使用过量为民众药物使用过量致死的最常见原因,2014年较往年增加了9%,海洛因使用过量致死的民众人数增加26%,合成阿片类药物(包括合成型的芬太尼和除美沙酮之外的合成阿片类止痛药)使用过量的死亡民众人数增加了80%。

CDC认为,2014年,几乎每一种阿片类药物过量导致的民众死亡人数都严重增多。CDC认为,阿片类止痛药和海洛因处方开具增多为主因。

在2014年,共有47055名民众因药物过量导致死亡,较去年增加了6.5%,死亡率由2013年的13.8/10万人升至2014年的14.7/10万人。 阿片类药物过量死亡的民众人数大幅上涨,从2013年的7.9/10万人升至9.0/10万人,增长了14%。其中28647人的死亡与阿片类药物使用过量有关,占61%;自2000年以来至今,使用阿片类药物过量的发生率翻番。无论性别、种族、年龄,死于过量使用阿片类药物的人数都增加,其中死亡率最高的西弗吉尼亚州、新墨西哥、新罕布什尔州、肯塔基州和俄亥俄州。

CDC解释道,两种背道而驰但又相互关联的因素导致药物滥用呈现流行趋势:15年来阿片类药物持续滥用和误用;吸食海洛因的民众人数日益增多。2014年,这两大问题呈现加剧和恶化趋势,因此导致使用阿片类药物过量导致死亡的民众人数增多。

2014年,在服用阿片类药物(包括阿片类止痛药和海洛因)过量的民众中,死亡率超3/5,其中所占比例最高的为死于合成阿片类药物(不包括美沙酮)的患者,达5500人,几乎为2013年的2倍,涨幅为26%。

研究人员认为,医生开具阿片类药物处方增多、民众对阿片类药物的依赖性增强、阿片类药物较低廉且容易购买、海洛因纯度高等原因在其中发挥了不可忽略的影响。

Tom Frieden博士认为这为广大民众敲响了警钟,因为它会为美国家庭带来毁灭性的打击。为了遏制阿片类药物滥用的流行趋势,挽救更多的患者,采取行动刻不容缓。相关部门必须加大惩治力度,严格查处海洛因等非法药物。

CDC建议可从4个方面预防:

1.医务人员限制开具阿片类药物处方;
2.对阿片类药物滥用患者采取治疗;
3.通过增加纳洛酮的使用以治疗阿片类药物使用障碍患者;
4.对阿片类使用障碍的患者,可采用包括药物辅助治疗等在内的多样化治疗方案。

研究人员希望,政府、公共卫生机构和执法机构等共同努力,共同采取措施,以避免阿片类药物过量使用爆发现象的出现。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=60056, encodeId=422a60056a3, content=无能为力, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 21:02:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48064, encodeId=05a3480644c, content=规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 14:44:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47932, encodeId=635e4e9323c, content=看如何使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 11:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47827, encodeId=2d9f4e827c9, content=祸害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151022/IMG5628D6F14DBD16799.jpg, createdBy=ed8e1658452, createdName=靶细胞, createdTime=Sat Dec 26 00:07:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252995, encodeId=87f312529956b, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309007, encodeId=6e8b130900eb8, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992244, encodeId=ef181992244f7, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Mon May 16 06:27:00 CST 2016, time=2016-05-16, status=1, ipAttribution=)]
    2016-01-26 收获你的美

    无能为力

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=60056, encodeId=422a60056a3, content=无能为力, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 21:02:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48064, encodeId=05a3480644c, content=规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 14:44:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47932, encodeId=635e4e9323c, content=看如何使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 11:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47827, encodeId=2d9f4e827c9, content=祸害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151022/IMG5628D6F14DBD16799.jpg, createdBy=ed8e1658452, createdName=靶细胞, createdTime=Sat Dec 26 00:07:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252995, encodeId=87f312529956b, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309007, encodeId=6e8b130900eb8, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992244, encodeId=ef181992244f7, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Mon May 16 06:27:00 CST 2016, time=2016-05-16, status=1, ipAttribution=)]
    2015-12-26 忠诚向上

    规范

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=60056, encodeId=422a60056a3, content=无能为力, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 21:02:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48064, encodeId=05a3480644c, content=规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 14:44:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47932, encodeId=635e4e9323c, content=看如何使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 11:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47827, encodeId=2d9f4e827c9, content=祸害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151022/IMG5628D6F14DBD16799.jpg, createdBy=ed8e1658452, createdName=靶细胞, createdTime=Sat Dec 26 00:07:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252995, encodeId=87f312529956b, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309007, encodeId=6e8b130900eb8, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992244, encodeId=ef181992244f7, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Mon May 16 06:27:00 CST 2016, time=2016-05-16, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    看如何使用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=60056, encodeId=422a60056a3, content=无能为力, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 21:02:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48064, encodeId=05a3480644c, content=规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 14:44:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47932, encodeId=635e4e9323c, content=看如何使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 11:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47827, encodeId=2d9f4e827c9, content=祸害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151022/IMG5628D6F14DBD16799.jpg, createdBy=ed8e1658452, createdName=靶细胞, createdTime=Sat Dec 26 00:07:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252995, encodeId=87f312529956b, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309007, encodeId=6e8b130900eb8, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992244, encodeId=ef181992244f7, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Mon May 16 06:27:00 CST 2016, time=2016-05-16, status=1, ipAttribution=)]
    2015-12-26 靶细胞

    祸害

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=60056, encodeId=422a60056a3, content=无能为力, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 21:02:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48064, encodeId=05a3480644c, content=规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 14:44:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47932, encodeId=635e4e9323c, content=看如何使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 11:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47827, encodeId=2d9f4e827c9, content=祸害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151022/IMG5628D6F14DBD16799.jpg, createdBy=ed8e1658452, createdName=靶细胞, createdTime=Sat Dec 26 00:07:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252995, encodeId=87f312529956b, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309007, encodeId=6e8b130900eb8, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992244, encodeId=ef181992244f7, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Mon May 16 06:27:00 CST 2016, time=2016-05-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=60056, encodeId=422a60056a3, content=无能为力, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 21:02:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48064, encodeId=05a3480644c, content=规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 14:44:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47932, encodeId=635e4e9323c, content=看如何使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 11:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47827, encodeId=2d9f4e827c9, content=祸害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151022/IMG5628D6F14DBD16799.jpg, createdBy=ed8e1658452, createdName=靶细胞, createdTime=Sat Dec 26 00:07:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252995, encodeId=87f312529956b, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309007, encodeId=6e8b130900eb8, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992244, encodeId=ef181992244f7, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Mon May 16 06:27:00 CST 2016, time=2016-05-16, status=1, ipAttribution=)]
    2015-12-24 lhlxtx
  7. [GetPortalCommentsPageByObjectIdResponse(id=60056, encodeId=422a60056a3, content=无能为力, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwlM29ic8TDJMJOiarryMIZZhTjXxyRT9lffSWpWWcWojnL7ibJwcOn99ayict8FJ9ICYmNh9swD6R4E/0, createdBy=196f1683049, createdName=收获你的美, createdTime=Tue Jan 26 21:02:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48064, encodeId=05a3480644c, content=规范, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sat Dec 26 14:44:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47932, encodeId=635e4e9323c, content=看如何使用, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 11:17:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47827, encodeId=2d9f4e827c9, content=祸害, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151022/IMG5628D6F14DBD16799.jpg, createdBy=ed8e1658452, createdName=靶细胞, createdTime=Sat Dec 26 00:07:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252995, encodeId=87f312529956b, content=<a href='/topic/show?id=13159e8871d' target=_blank style='color:#2F92EE;'>#阿片类药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97887, encryptionId=13159e8871d, topicName=阿片类药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1309007, encodeId=6e8b130900eb8, content=<a href='/topic/show?id=a0179e879ac' target=_blank style='color:#2F92EE;'>#阿片类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97879, encryptionId=a0179e879ac, topicName=阿片类)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Thu Dec 24 11:27:00 CST 2015, time=2015-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1992244, encodeId=ef181992244f7, content=<a href='/topic/show?id=7e5a492636a' target=_blank style='color:#2F92EE;'>#应对策略#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49263, encryptionId=7e5a492636a, topicName=应对策略)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Mon May 16 06:27:00 CST 2016, time=2016-05-16, status=1, ipAttribution=)]

相关资讯

JAMA Intern Med:防止阿片类药物滥用的新策略

美国佛罗里达州一直致力于减少处方阿片类药物的滥用和处方分配问题,一项发表于JAMA Internal Medicine中的最新研究显示,通过处方药物管理办法(PDMPs)和“药物滥用”法使得阿片类药物处方的开具和使用有了一定的缓解。“PDMPs和药物滥用法为解决处方药物滥用的流行趋势提供了有效地解决方法”,来自霍普金斯大学彭博公共卫生学院的首席科学家兰尼·卢特考如是说。&nbs

JAMA:美国近十年阿片类药物使用情况分析——借鉴意义重大

自从1999年以来,由于处方类阿片镇痛药的非医疗用途的使用导致的死亡率和发病率在美国呈现逐年上升的趋势。在这段时间内,由于这些镇痛药的不当使用导致的急诊室人数上升和药物过量使用导致的死亡不断的上升。 据估计,由于阿片类镇痛药的使用导致的急诊就诊人数从2004年的每十万人中有82.5上升至每十万人中有184.1人。由此可见,处方阿片类镇痛药的滥用已经成为美国医疗卫生的一大问题。 

Lancet Psychiatry:阿片类药物替代疗法(美沙酮vs丁丙诺啡)的死亡风险比较

阿片类药物依赖性增加了过早死亡的风险。使用美沙酮或丁丙诺啡替代阿片类药物治疗可降低死亡风险,尤其是对与药物过量有关的死亡。临床指南推荐美沙酮作为阿片类药物替代治疗的一线药物。该研究的目的是测试丁丙诺啡治疗是否比美沙酮治疗具有较低的死亡风险,通过比较在治疗诱导时,治疗过程药物的转换和治疗后停止用药的全因死亡率进行分析。研究人员在澳大利亚新南威尔士州做了一项所有具有阿片类药物依赖性患者的回顾性队列研究

一周研究进展荟萃:让你知识满满!

通宵工作 癌细胞 β受体阻滞剂 睡眠 阿片类药物 心衰 动脉硬化

JCO:癌症中度疼痛使用低剂量吗啡镇痛,效果显著!

 WHO针对癌症疼痛治疗是基于一种三步、镇痛梯度。第一步是使用非阿片类镇痛药来治疗轻微的疼痛,比如扑热息痛或者非甾体类抗炎药物;第二步是使用弱的阿片类药物,如:可待因或者曲马朵来治疗轻微至中度的疼痛;第三步是使用强效阿片类药物来治疗中度疼痛。尽管这种梯度已经被广泛用于临床治疗癌症引发的疼痛,但是没有被缓解的疼痛仍然对实体瘤或者血液恶性肿瘤患者造成巨大的影响。一个常见的原因就是镇痛治疗不足